MK-6837 has been discontinued, the company discloses.
ApexOnco Front Page
Recent articles
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
The two companies have been involved in recent licensing deals.
Dispatch Bio’s virus therapy DV-10 enters phase 1.
The company discontinues the Lag3 project in lung cancer.
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
